UCL Technology Fund investment MeiraGTx raises $75m at IPO

UCL Technology Fund investment MeiraGTx Holdings plc (‘MeiraGTx’), the clinical stage gene therapy company, has raised $75million at IPO, pricing five million shares at $15.00 per share on the Nasdaq Global Select Market on June 12 2018. The UCL Technology Fund (UCLTF) is managed by Albion Capital in collaboration with UCL Business (UCLB), UCL’s commercialisation […]

Read more

Bloomsbury AI joins the Facebook Team in London

UCL Technology Fund is very proud to have backed Bloomsbury AI and we are delighted that they are joining the Facebook team in London. For the full story please follow the link below Bloomsbury AI joins the London Facebook Team

Read more

Matr raises £4.75 million for AI teaching platform

Matr, the online teaching platform, has announced it has closed a £4.75 million Series A investment round led by the UCL Technology Fund and Downing Ventures, with follow on investment from Ananda and innovation charity Nesta, and Sherry Coutu joining as an angel investor. The company has now raised £8.25 million in funding. Following an […]

Read more

Freeline secures over £88 million of funding

London, 19 June 2018 – Freeline Therapeutics Ltd (“Freeline”), a clinical stage company focused on treatment of chronic systemic diseases with liver targeted adeno-associated virus (AAV) gene therapy, announces today that it has raised over £88 million of new capital in a Series B financing round. Syncona Ltd (“Syncona”) led the new investment committing £85 […]

Read more

UCL Technology Fund has approved investment of up to £1m in the development of a gene therapy for (Perforin deficient) Familial Haemophagocytic Lymphohistiocytosis

The UCL Technology Fund (UCLTF) has approved an investment of up to £1m to support Professor Bobby Gaspar’s development of a gene therapy for (perforin deficient) familial haemophagocytic lymphohistiocytosis (FHL type 2 or ‘FHL-2’) through to a clinical trial in which it could potentially cure patients of a rare but deadly inherited disease. FHL-2 is […]

Read more

Orchard Therapeutics has been awarded Deal of the Year by Global University Venturing

An oversubscribed $110m series B round completed in December 2o17 made Orchard Therapeutics an obvious choice for the 2018 Global University Venturing Deal of the Year award. The series B round was co-led by investment firm Baillie Gifford and venture capital firm Ori Capital, and featured contributions from the UCL Technology Fund and Singaporean state-owned […]

Read more

UCL Technology Fund Showcase 2018

UCLTF Showcase – standing room only The inaugural UCL Technology Fund Showcase, held at Digital Catapult, brought together two years of investing in world-leading and world-changing UCL technologies and innovations that will have a real and positive impact on our lives. From gene therapies looking to cure fatal diseases to AI enhanced education platforms, the variety and range […]

Read more

UCL Technology Fund and UK Innovation & Science Seed Fund invest in cell therapy company Glialign

The UCL Technology Fund (UCLTF), UK Innovation & Science Seed Fund (UKI2S), alongside support from Innovate UK, have invested in UCL spinout company Glialign Ltd, which is developing a novel cell therapy for peripheral nerve repair. Hundreds of thousands of people every year are affected by severe peripheral nerve damage, resulting in paralysis and loss […]

Read more